Several global funds, including Blackstone, Carlyle, PAG, CVC Capital, BPEA EQT, Brookfield Asset Management, and Apax Partners, have expressed interest in acquiring Hyderabad-based pharmaceutical company Sai Life Sciences, according to multiple people familiar with the situation. TPG Capital currently owns approximately 43.3% of Sai Life, while Swiss-healthcare fund HBM Private Equity India owns 6%, and the promoter Kanumuri family owns the remaining stake.

According to sources, the promoter is seeking a valuation of $800 million (Rs. 6,500 crore) for the company. According to a PE fund manager interested in the buyout, the company is likely to be valued in the $500 million (4,000 crore) range.

Sai Life is an integrated contract research & manufacturing services provider, and provides drug discovery, development, and manufacturing services to leading global pharmaceuticals & biotechnology companies. The company is also engaged in generic API (active pharmaceutical ingredients) and formulation supply upon the product going off-patent.

Telangana, Karnataka, and Maharashtra are where the company's manufacturing and R&D facilities are located.

Sai Life Sciences, founded in 1999, began with medicinal chemistry services and later expanded its service offerings to include process research and development services in 2002. According to the Care Ratings report, the company entered into contract manufacturing services in 2005 with the acquisition of Prasad Drugs, followed by the acquisition of Merrifield Pharma in Karnataka in 2006 to expand manufacturing capabilities.